CHI Logo

 

Overview
Register
Hotel & Travel
Sponsor
Exhibits
Press Pass
Request Brochure

 

 

Corporate Sponsor


ThermoScientific

Targeting Diabetes With Novel Therapeutics

 

Overview | Day 1 | Day 2 | Download Brochure 

SESSIONS

Promising Drug Targets for Diabetes

Novel Approaches for New Therapies

A Closer Look at Incretins

PANEL DISCUSSION

Topic: The Future of Incretins as a Target for Diabetes

Participants:
Richard E. Pratley, M.D., Professor of Medicine and Director, Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine
Rachele Berria, M.D., M.S.C.I., U.S. Medical Director, Diabetes Franchise, Roche Laboratories
Michael R. Hanley, Ph.D.,Chief Scientific Officer, Amylin Pharmaceuticals, Inc.

DISTINGUISHED FACULTY
Rachele Berria, M.D., Roche Laboratories
Elaine Chiquette, Amylin Pharmaceuticals Inc.
Max Dang, Ph.D., Metabasis Therapeutics, Inc.
Joseph Grimsby, Ph.D., F. Hoffmann-La Roche Inc.
Jesper Gromada, Ph.D., Novartis Institutes for BioMedical Research, Inc.
Michael R. Hanley, Ph.D., Amylin Pharmaceuticals, Inc.
Richard Ho, M.D., Ph.D., Rosa & Co. LLC.
Reid Huber, Ph.D., Metabolic Endocrine Drug Development, Incyte Corporation
Rob Jones, Ph.D., Arena Pharmaceuticals
Julia Lamenzo Ph.D., Harvard University
Daniel Lin, Ph.D., Amgen Inc.
Peter J. Oates, Ph.D., Pfi zer Global Research and Development
Norbert Perrimon, Ph.D., Harvard Medical School
Richard E. Pratley, M.D., University of Vermont College of Medicine
Jean Whaley, Ph.D., Bristol-Myers Squibb

 

Click the links below to
view Discovery On Target 2008
RNAI RB
TVD RB
KIT RB
HDAC RB
ION RB
Targeting RB